Cabazitaxel, a novel taxane, was approved in June 2010 by the U.S. Food and Drug Admini-stration for treatment of metastatic castrate-resistant prostate cancer (mCRPC) in men previously treated with docetaxel. In TROPIC (N = 755), an open-label, randomized, phase III trial, cabazitaxel (plus...